Trial Profile
A Randomized, Placebo-controlled Trial of BPS804 on Safety and Tolerability in Patients With Late-stage Chronic Kidney Disease
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 16 Sep 2022
Price :
$35
*
At a glance
- Drugs Setrusumab (Primary)
- Indications Osteogenesis imperfecta
- Focus Adverse reactions
- Sponsors Novartis; Ultragenyx Pharmaceutical
- 16 Sep 2022 The trial is prematurely ended in UK.
- 30 Oct 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 22 Oct 2013 New trial record